Skip to content

Trial Summary

This is a phase 1b open-label, multi-centre, dose escalation study of Pexa-Vec (Thyidine Kinase- deactivated vaccinia virus plus GM-CSF) in combination with REGN2810 (anti-PD-1) in patients with metastatic or unresectable renal cell carcinoma (RCC).

Acronym:

CS1001-101

ACTRN/NCT /ethics:

NCT03312842

Scientific title:

A Phase Ia/Ib Study of CS1001 in Subjects With Advanced Solid Tumors

Sponsor / Cooperative group:

Cstone Pharmaceuticals

Trial & Patient Characteristics

Cancer TypeAll cancers
Trial TypeTreatment
PhasePhase I
Age Range18 years to 75 years
SexBoth
Tumour Stream -
Cancer StageLocally Recurrent or Locally Advanced, Metastatic or Widespread
Anticipated Start Date2017-10-19
Anticipated End Date2022-08-01

Participating Hospitals

HospitalAshford Cancer Centre Research
Clinical Trial CoordinatorSue Yeend
Emailsyeend@adelaidecancercentre.com.au
Phone08 8292 2240
Principal InvestigatorDr Anna Mislang
Recruitment StatusRecruiting